SI1869056T1 - Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati - Google Patents
Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivatiInfo
- Publication number
- SI1869056T1 SI1869056T1 SI200630886T SI200630886T SI1869056T1 SI 1869056 T1 SI1869056 T1 SI 1869056T1 SI 200630886 T SI200630886 T SI 200630886T SI 200630886 T SI200630886 T SI 200630886T SI 1869056 T1 SI1869056 T1 SI 1869056T1
- Authority
- SI
- Slovenia
- Prior art keywords
- thiazoloy4
- amino
- substituted
- novel
- pyrimidine derivatives
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500767 | 2005-04-06 | ||
| EP06717078A EP1869056B1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives |
| PCT/SE2006/000399 WO2006107258A1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1869056T1 true SI1869056T1 (sl) | 2011-02-28 |
Family
ID=37073739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200630886T SI1869056T1 (sl) | 2005-04-06 | 2006-04-03 | Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7947693B2 (OSRAM) |
| EP (1) | EP1869056B1 (OSRAM) |
| JP (1) | JP5165553B2 (OSRAM) |
| KR (1) | KR101335055B1 (OSRAM) |
| CN (1) | CN101193897B (OSRAM) |
| AR (1) | AR055890A1 (OSRAM) |
| AT (1) | ATE487727T1 (OSRAM) |
| AU (1) | AU2006231836B2 (OSRAM) |
| BR (1) | BRPI0609738A2 (OSRAM) |
| CA (1) | CA2604017C (OSRAM) |
| CY (1) | CY1111316T1 (OSRAM) |
| DE (1) | DE602006018124D1 (OSRAM) |
| DK (1) | DK1869056T3 (OSRAM) |
| ES (1) | ES2354450T3 (OSRAM) |
| HR (1) | HRP20110047T1 (OSRAM) |
| IL (1) | IL185912A0 (OSRAM) |
| MX (1) | MX2007012060A (OSRAM) |
| NO (1) | NO20075603L (OSRAM) |
| NZ (1) | NZ561460A (OSRAM) |
| PL (1) | PL1869056T3 (OSRAM) |
| PT (1) | PT1869056E (OSRAM) |
| RS (1) | RS51581B (OSRAM) |
| RU (1) | RU2419623C2 (OSRAM) |
| SA (1) | SA06270072B1 (OSRAM) |
| SI (1) | SI1869056T1 (OSRAM) |
| TW (1) | TW200714605A (OSRAM) |
| UA (1) | UA90707C2 (OSRAM) |
| UY (1) | UY29454A1 (OSRAM) |
| WO (1) | WO2006107258A1 (OSRAM) |
| ZA (1) | ZA200708187B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| RU2437889C2 (ru) * | 2006-09-29 | 2011-12-27 | Астразенека Аб | НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ |
| PL2254870T3 (pl) | 2008-03-07 | 2016-07-29 | Acraf | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1 |
| GEP20135913B (en) | 2008-03-07 | 2013-08-26 | Acraf | 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression |
| MX2010009625A (es) | 2008-03-07 | 2010-09-28 | Acraf | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. |
| AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| EP2648754A4 (en) | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHOD OF INHIBITING CANCER METASTASES |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| KR20150129698A (ko) | 2013-03-12 | 2015-11-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피롤리딘-3-일 아세트산 유도체의 염 및 그의 결정 |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| US20180222922A1 (en) * | 2015-06-08 | 2018-08-09 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| WO2018204370A1 (en) | 2017-05-02 | 2018-11-08 | Drexel University | Cx3cr1 small molecule antagonists, and methods using same |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
| CN120077035A (zh) | 2022-10-19 | 2025-05-30 | 阿斯利康(瑞典)有限公司 | 作为cx3cr1的调节剂的2,4,6-三取代的1,3,5-三嗪 |
| WO2025219939A1 (en) | 2024-04-17 | 2025-10-23 | Astrazeneca Ab | Salts and polymorphs of cx3cr1 modulators |
| WO2025219950A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
| WO2025219947A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Thio-substituted 1,3,5-triazine cx3cr1 modulators |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE543978A (OSRAM) | 1955-01-03 | |||
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| CA2031803C (en) | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| ATE214704T1 (de) * | 1997-07-18 | 2002-04-15 | Hoffmann La Roche | 5h-thiazolo(3,2-a)pyrimidinderivate |
| WO1999051608A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| AU2881399A (en) | 1998-05-01 | 1999-11-23 | Eli Lilly And Company | N1-modified glycopeptides |
| SE9802729D0 (sv) * | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359081A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| DE60101372T2 (de) | 2000-02-11 | 2004-10-14 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AU2003299795A1 (en) * | 2002-12-20 | 2004-07-22 | Xeris Pharmaceuticals, Inc. | Intracutaneous injection |
| EP1675862A1 (en) | 2003-10-07 | 2006-07-05 | AstraZeneca AB | New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| JP2008524186A (ja) * | 2004-12-17 | 2008-07-10 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物 |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active Expired - Fee Related
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de active Active
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en not_active Ceased
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en active Active
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja active Active
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 RS RS20110006A patent/RS51581B/sr unknown
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es active Active
- 2006-04-03 HR HR20110047T patent/HRP20110047T1/hr unknown
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh active Active
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL185912A0 (en) | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
| ZA200705040B (en) | 2,4 (4,6) pyrimidine derivatives | |
| ZA200805294B (en) | Pyrimidine derivatives | |
| IL181433A0 (en) | Pyrimidine derivatives | |
| IL181386A0 (en) | Pyrimidine derivatives | |
| GB0415364D0 (en) | Pyrimidine derivatives | |
| ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
| DK1797099T3 (da) | Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser | |
| IL186661A0 (en) | Heterocyclic antiviral compounds | |
| GB0525080D0 (en) | Pyrimidine derivatives | |
| AP2005003403A0 (en) | Substituted pyrimidinones. | |
| ZA200804301B (en) | 1,5-substituted indol-2-yl amide derivatives | |
| GB0525083D0 (en) | Pyrimidine derivatives | |
| ZA200805354B (en) | Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives | |
| SMAP200800029A (it) | 2-ammino-7,8-diidro-6h.pirido[4,3-d]pirimidin-5-oni | |
| GB0415367D0 (en) | Pyrimidine derivatives | |
| IL179914A0 (en) | Pyrimidine derivatives | |
| AP2281A (en) | Novel compounds. | |
| GB0525081D0 (en) | Pyrimidine derivatives | |
| PL1644343T3 (pl) | Pochodne 5-podstawionego chinazolinonu | |
| AP2157A (en) | 2-substituted pyrimidines. | |
| IL186221A0 (en) | Crystalline rosuvastatin intermediate | |
| ZA200700162B (en) | Novel heterocyclic compounds | |
| TWI315670B (en) | Substituted aryl 1,4-pyrazine derivatives | |
| IL186226A0 (en) | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |